Clinical Trials Logo

Driving Performance clinical trials

View clinical trials related to Driving Performance.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04590495 Completed - Clinical trials for Cognitive Impairment

The Effects of Cannabidiol on the Driving Ability of Healthy Adults

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

A randomized, parallel-group, double-blind, exploratory two-arm trial to assess the effects of CBD on driving ability along with changes in psychological status (i.e. mood, drowsiness, sedation) and cognitive function. Forty healthy West Virginia University (WVU) students will be allocated and randomized to receive: (1) 300 mg of pure CBD oil or (N=20) (2) placebo matched in appearance and taste (N=20). After consuming the study drug, each individual will participate in a 25-35-minute driving simulation and their driving performance measured. To assess changes in psychological status (i.e. mood, drowsiness, sedation) and drug impairment-related cognitive function, the Visual Analog Mood Scale, Stanford Sleepiness Scale , Digital Symbol Substitution Test, Trail Making Test Part A and B, Psychomotor Vigilance Test, and Simple Reaction Time test will also be administered to participants at baseline (prior to study drug consumption) and following completion of the driving simulation test. The entire protocol will be completed in one day and should take 4-4.5 hours to complete for each participant.

NCT ID: NCT03814733 Completed - Driving Performance Clinical Trials

Assessment of Effect of Rapastinel on Driving Performance

Start date: November 5, 2018
Phase: Phase 1
Study type: Interventional

Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy participants.